Table 3.
Immune status of breast cancer patients before treatment and after 6 cycles of chemotherapy without Uncaria tomentosa supply (Ca group) or receiving 300 mg/day of Uncaria tomentosa (UtCa group).
| Parameters | Group | Chemotherapy cycles | |
|---|---|---|---|
| 0 | 6 | ||
| CD4+ T cells | UtCa | 1008.25 (379.21) | 786.60 (310.49) |
| Cells/μL | Ca | 1053.00 (620.81) | 798.00 (366.14) |
|
| |||
| CD8+ T cells | Ut Ca | 568.81 (295.60) | 459.87 (246.46) |
| Cells/μL | Ca | 679.84 (273.22) | 565.62 (231.05) |
|
| |||
| CD4+ T/CD8+ T ratio | UtCa | 2.044 (0.62) | 1.858 (0.89) |
| Ca | 1.630 (0.69) | 1.652 (0.49) | |
|
| |||
| IL6 | UtCa | 3.4 (4.50) | 2.1 (6.6) |
| pg/mL | Ca | 5.6 (5.53) | 3.8 (7.312) |
Data expressed as mean ± standard deviation; UtCa group: patients treated with chemotherapy +300 mg Uncaria tomentosa daily (n = 20); Ca group: patients received chemotherapy (n = 20).